

STATISTICAL COMPENDIUM: MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT IN 2002 ALABAMA

LIST OF TABLES

OVERVIEW OF STUDY POPULATION

TABLE 1. OVERVIEW OF BENEFICIARY SELECTION CRITERIA FOR STUDY POPULATION

FOR ALL MEDICAID BENEFICIARIES

TABLE 2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE 3. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE 4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE 5. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC

TABLE 6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE 7. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

FOR ALL NONDUAL BENEFICIARIES

TABLE ND.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE ND.3. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE ND.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE ND.5. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC

TABLE ND.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE ND.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

TABLE ND.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC

TABLE ND.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE ND.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP 10 DRUG GROUP

TABLE ND.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS, BY BENEFICIARY CHARACTERISTIC

TABLE ND.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE ND.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG NONDUALS

FOR DUAL ELIGIBLE BENEFICIARIES

- TABLE D.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY
- TABLE D.3. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC
- TABLE D.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE D.5. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC
- TABLE D.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE D.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP
- TABLE D.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC
- TABLE D.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE D.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP 10 DRUG GROUP
- TABLE D.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS, BY BENEFICIARY CHARACTERISTIC
- TABLE D.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE D.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG DUALS

SUPPLEMENTAL TABLES

- SUPPLEMENTAL TABLE 1. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES
- SUPPLEMENTAL TABLE 1A. MEDICAID PHARMACY REIMBURSEMENT FOR DISABLED DUAL ELIGIBLE BENEFICIARIES UNDER AGE 65
- SUPPLEMENTAL TABLE 1B. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 AND OLDER
- SUPPLEMENTAL TABLE 1C. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 TO 74
- SUPPLEMENTAL TABLE 1D. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 75 TO 84
- SUPPLEMENTAL TABLE 1E. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 85 AND OLDER

APPENDIX TABLE

- APPENDIX TABLE A.1. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, NONDUAL BENEFICIARIES
- APPENDIX TABLE A.2. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, NONDUAL BENEFICIARIES
- APPENDIX TABLE A.3. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, DUAL ELIGIBLE BENEFICIARIES
- APPENDIX TABLE A.4. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, DUAL ELIGIBLE BENEFICIARIES

TABLE ND.2
 CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY^{a, b}
 NONDUAL BENEFICIARIES, ALABAMA, 2002

Beneficiary Characteristics	No. of Benefes							No. of Bene Mos				
	All	Aged	Disabled	Adults	Children	Other/ Unknown	All	Aged	Disabled	Adults	Children	Other/ Unknown
All	671,804	1,053	108,922	138,788	422,859	182	6,590,109	9,072	1,168,829	1,384,150	4,026,622	1,436
Age												
5 and younger	183,691	0	6,795	0	176,896	0	1,715,744	0	72,457	0	1,643,287	0
6-14	185,952	0	17,872	0	168,080	0	1,876,284	0	203,783	0	1,672,501	0
15-20	90,429	0	12,196	738	77,495	0	851,532	0	135,107	7,773	708,652	0
21-44	169,585	0	33,676	135,477	388	44	1,719,552	0	359,828	1,357,177	2,182	365
45-64	39,253	7	36,542	2,566	0	138	397,151	31	376,873	19,176	0	1,071
65-74	1,801	277	1,524	0	0	0	19,922	2,605	17,317	0	0	0
75-84	647	391	256	0	0	0	6,406	3,586	2,820	0	0	0
85 and older	446	378	61	7	0	0	3,518	2,850	644	24	0	0
Unknown	0	0	0	0	0	0	0	0	0	0	0	0
Gender												
Female	413,838	732	57,431	136,949	218,544	182	4,088,422	6,144	624,580	1,372,184	2,084,078	1,436
Male	252,171	318	51,489	1,839	198,525	0	2,468,970	2,906	544,225	11,966	1,909,873	0
Unknown	5,795	3	2	0	5,790	0	32,717	22	24	0	32,671	0
Race												
White	286,010	529	41,445	63,215	180,720	101	2,731,544	4,120	437,010	618,977	1,670,605	832
African American	351,563	340	54,870	72,781	223,494	78	3,534,187	3,035	605,300	738,699	2,186,566	587
Other/unknown	34,231	184	12,607	2,792	18,645	3	324,378	1,917	126,519	26,474	169,451	17
Use of Nursing Facilities^c												
Entire year	1,033	203	829	0	1	0	10,668	1,887	8,770	0	11	0
Part year	646	84	559	1	2	0	6,506	784	5,697	10	15	0
None	670,125	766	107,534	138,787	422,856	182	6,572,935	6,401	1,154,362	1,384,140	4,026,596	1,436
Maintenance Assistance Status												
Cash	210,533	572	107,317	25,934	76,710	0	2,142,284	6,057	1,156,564	220,762	758,901	0
Medically needy	0	0	0	0	0	0	0	0	0	0	0	0
Poverty-related	342,283	14	60	15,752	326,275	182	3,199,478	71	236	119,810	3,077,925	1,436
Other/unknown	118,988	467	1,545	97,102	19,874	0	1,248,347	2,944	12,029	1,043,578	189,796	0
Managed Care Status												
FFS all year	671,794	1,050	108,915	138,788	422,859	182	6,590,054	9,056	1,168,790	1,384,150	4,026,622	1,436
FFS part year, with Rx claims	10	3	7	0	0	0	55	16	39	0	0	0
FFS part year, no Rx claims	0	0	0	0	0	0	0	0	0	0	0	0

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

- a. Table ND.2 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.
- c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; Rx = pharmacy benefit.

TABLE ND.3

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC^{a,b}
 NONDUAL BENEFICIARIES, ALABAMA, 2002

Beneficiary Characteristics	% with at Least One Rx	Mean No. of Rx	Mean Rx \$	\$ per Rx	Mean \$, All Services	Rx \$ as % of All Services	No. of Benes
All	61.4 %	8.0	\$379	\$47	\$2,118	17.9 %	671,804
Age							
5 and younger	74.9	5.9	225	38	1,624	13.8	183,691
6-14	63.8	5.2	278	54	1,751	15.9	185,952
15-20	59.5	5.1	259	51	2,294	11.3	90,429
21-44	39.4	6.8	344	51	1,904	18.1	169,585
45-64	85.4	41.3	1,913	46	6,178	31.0	39,253
65-74	83.2	39.7	1,681	42	7,965	21.1	1,801
75-84	75.4	35.6	1,456	41	10,462	13.9	647
85 and older	58.3	24.0	920	38	11,476	8.0	446
Unknown	0.0	0.0	0	0	0	0.0	0
Basis of Eligibility^c							
Aged	65.3	27.8	1,138	41	9,871	11.5	1,053
Disabled	80.9	26.6	1,497	56	5,615	26.7	108,922
Adults	30.2	2.9	92	31	1,019	9.0	138,788
Children	66.6	4.8	182	38	1,556	11.7	422,859
Unknown	89.6	19.4	981	51	8,931	11.0	182
Gender							
Female	57.3	8.2	354	43	1,984	17.9	413,838
Male	68.6	7.8	425	54	2,349	18.1	252,171
Unknown	49.0	2.4	87	36	1,670	5.2	5,795
Race							
White	65.5	9.8	463	47	2,328	19.9	286,010
African American	57.7	6.1	283	46	1,885	15.0	351,563
Other/unknown	66.1	12.5	661	53	2,755	24.0	34,231
Use of Nursing Facilities^d							
Entire year	99.1	67.4	3,389	50	44,241	7.7	1,033
Part year	98.9	64.2	3,277	51	27,029	12.1	646
None	61.3	7.9	371	47	2,029	18.3	670,125
Maintenance Assistance Status							
Cash	73.1	16.5	867	53	3,562	24.3	210,533
Medically needy	0.0	0.0	0	0	0	0.0	0
Poverty related	68.4	4.9	183	37	1,393	13.1	342,283
Other/unknown	20.8	1.9	78	41	1,650	4.7	118,988

Table ND3

Nondual Beneficiaries

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

- a. Table ND.3 includes beneficiaries represented by Cell K of Table 1.
 - b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
 - c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
 - d. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.
- Bene(s) = beneficiary (or beneficiaries); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.4
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC^{a,b}
 NONDUAL BENEFICIARIES, ALABAMA, 2002

Beneficiary Characteristics	Mean No. of Rx	Mean Rx \$	Rx \$ as % of All Services	No. of Rx, % with:					Mean \$, All Services	Benes	Bene Mos	
				None	More than 0, but 1 or Less	More than 1, but 2 or Less	More than 2, but 5 or Less	More than 5, but 10 or Less				More than 10
All	0.8	\$39	17.9 %	38.6 %	47.4 %	6.3 %	5.2 %	2.0 %	0.4 %	\$216	671,804	6,590,109
Age												
5 and younger	0.6	24	13.8	25.1	64.5	7.7	2.6	0.1	0.0	174	183,691	1,715,744
6-14	0.5	28	15.9	36.2	55.4	5.2	2.9	0.3	0.0	174	185,952	1,876,284
15-20	0.5	28	11.3	40.5	50.1	5.8	3.1	0.5	0.0	244	90,429	851,532
21-44	0.7	34	18.1	60.6	26.0	5.1	5.7	2.2	0.3	188	169,585	1,719,552
45-64	4.1	189	31.0	14.6	18.3	11.8	28.7	21.0	5.5	611	39,253	397,151
65-74	3.6	152	21.1	16.8	17.7	11.7	30.5	19.2	4.2	720	1,801	19,922
75-84	3.6	147	13.9	24.6	16.1	10.0	25.8	19.2	4.3	1,057	647	6,406
85 and older	3.0	117	8.0	41.7	11.9	6.3	21.3	16.8	2.0	1,455	446	3,518
Unknown	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0	0
Basis of Eligibility^c												
Aged	3.2	132	11.5	34.7	13.9	7.2	25.1	16.0	3.2	1,146	1,053	9,072
Disabled	2.5	140	26.7	19.1	34.3	12.2	20.5	11.3	2.6	523	108,922	1,168,829
Adults	0.3	9	9.0	69.8	23.9	3.3	2.3	0.6	0.1	102	138,788	1,384,150
Children	0.5	19	11.7	33.4	58.6	5.8	2.1	0.1	0.0	163	422,859	4,026,622
Unknown	2.5	124	11.0	10.4	30.2	20.9	33.0	5.5	0.0	1,132	182	1,436
Gender												
Female	0.8	36	17.9	42.7	43.4	5.8	5.1	2.4	0.6	201	413,838	4,088,422
Male	0.8	43	18.1	31.4	54.2	7.2	5.3	1.5	0.3	240	252,171	2,468,970
Unknown	0.4	16	5.2	51.0	40.8	5.9	2.2	0.1	0.0	296	5,795	32,717
Race												
White	1.0	48	19.9	34.5	47.7	7.9	6.5	2.7	0.7	244	286,010	2,731,544
African American	0.6	28	15.0	42.3	47.5	5.0	3.8	1.3	0.2	188	351,563	3,534,187
Other/unknown	1.3	70	24.0	33.9	44.6	7.5	8.2	4.6	1.1	291	34,231	324,378
Use of Nursing Facilities^d												
Entire year	6.5	328	7.7	0.9	6.0	7.6	30.1	40.5	14.9	4,284	1,033	10,668
Part year	6.4	325	12.1	1.1	8.2	7.7	30.7	37.3	15.0	2,684	646	6,506
None	0.8	38	18.3	38.7	47.5	6.3	5.1	2.0	0.4	207	670,125	6,572,935
Maintenance Assistance Status												
Cash	1.6	85	24.3	26.9	43.8	9.3	12.4	6.2	1.4	350	210,533	2,142,284
Medically needy	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0	0
Poverty related	0.5	20	13.1	31.6	59.9	6.2	2.2	0.1	0.0	149	342,283	3,199,478
Other/unknown	0.2	8	4.7	79.2	17.9	1.5	0.9	0.3	0.1	157	118,988	1,248,347

Table ND4

Nondual Beneficiaries

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

- a. Table ND.4 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- d. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.5
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC^{a, b, c}
 NONDUAL BENEFICIARIES, ALABAMA, 2002

Beneficiary Characteristics	All Rx		Patented Brand-Name Drugs		Off-Patent Brand-Name Drugs		Generic Drugs	
	No. of Rx	Rx \$	No. of Rx	\$ per Rx	No. of Rx	Rx \$	No. of Rx	Rx \$
All	0.8	\$39	0.3	\$28	0.1	\$3	0.4	\$7
Age								
5 and younger	0.6	24	0.3	18	0.1	2	0.3	4
6-14	0.5	28	0.2	20	0.1	3	0.2	4
15-20	0.5	28	0.2	21	0.1	3	0.3	4
21-44	0.7	34	0.2	25	0.1	2	0.4	7
45-64	4.1	189	1.6	136	0.2	11	2.2	43
65-74	3.6	152	1.4	108	0.2	9	2.0	35
75-84	3.6	147	1.4	104	0.2	9	2.0	34
85 and older	3.0	117	1.2	81	0.3	9	1.6	27
Unknown	0.0	0	0.0	0	0.0	0	0.0	0
Basis of Eligibility^d								
Aged	3.2	132	1.3	95	0.2	9	1.7	29
Disabled	2.5	140	1.0	105	0.2	8	1.3	26
Adults	0.3	9	0.1	6	0.0	1	0.2	2
Children	0.5	19	0.2	14	0.1	2	0.2	3
Unknown	2.5	124	1.0	101	0.1	3	1.3	20
Gender								
Female	0.8	36	0.3	26	0.1	3	0.4	7
Male	0.8	43	0.3	33	0.1	3	0.4	7
Unknown	0.4	16	0.1	12	0.0	1	0.3	3
Race								
White	1.0	48	0.4	35	0.1	4	0.5	9
African American	0.6	28	0.2	21	0.1	2	0.3	5
Other/unknown	1.3	70	0.5	53	0.1	4	0.7	12
Use of Nursing Facilities^e								
Entire year	6.5	328	2.4	232	0.6	26	3.5	69
Part year	6.4	325	2.3	228	0.5	26	3.5	72
None	0.8	38	0.3	28	0.1	3	0.4	7
Maintenance Assistance Status								
Cash	1.6	85	0.7	64	0.1	5	0.9	16
Medically needy	0.0	0	0.0	0	0.0	0	0.0	0
Poverty related	0.5	20	0.2	14	0.1	2	0.2	3
Other/unknown	0.2	8	0.1	5	0.0	1	0.1	1
\$ per Rx								
All		\$47	0.3	\$28	0.1	\$3	0.4	\$7
Patented Brand-Name Drugs		\$39	0.3	\$28	0.1	\$3	0.4	\$7
Off-Patent Brand-Name Drugs		\$42	0.1	\$3	0.1	\$3	0.4	\$7
Generic Drugs		\$18	0.3	\$28	0.1	\$3	0.4	\$7

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

- a. Table ND.5 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Alabama, 0.1 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all combined. For information about this classification method, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).
- d. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- e. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.6

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY^{a, b, c, d}
 NONDUAL BENEFICIARIES, ALABAMA, 2002

Therapeutic Category	No. of Rx per Bene Mo among Users			\$ per Bene Mo among Users			Total No. of Rx	Total Rx \$	No.	As % of All Benes	No. of Bene Mos					
	Users			Users												
	Total	Patented	Off-Patent	Total	Patented	Off-Patent										
Anti-infective Agents	0.3	0.1	0.0	\$11	\$8	\$1	\$2	\$42	\$62	\$69	\$14	783,378	\$32,678,634	290,151	43.2 %	3,086,717
Biologicals	0.3	0.3	0.0	375	329	7	38	1150	1,063	3,195	2,762	7,520	8,647,207	2,388	0.4	23,056
Antineoplastic Agents	0.5	0.2	0.0	107	90	4	13	224	413	115	59	10,954	2,453,926	2,158	0.3	22,871
Endocrine/Metabolic Drugs	0.4	0.2	0.0	18	14	1	3	46	65	33	19	390,738	17,839,987	92,270	13.7	1,003,091
Cardiovascular Agents	1.2	0.5	0.1	40	27	2	10	34	59	36	16	587,566	20,136,086	46,969	7.0	508,564
Respiratory Agents	0.4	0.2	0.1	15	10	2	3	38	62	30	17	1,096,190	41,159,738	257,892	38.4	2,753,566
Gastrointestinal Agents	0.4	0.1	0.0	8	7	0	1	43	100	148	20	221,291	9,424,404	56,840	8.5	610,318
Genitourinary Agents	0.2	0.2	0.0	57	48	2	8	77	124	84	24	62,123	2,502,389	28,843	4.3	304,926
CNS Drugs	0.7	0.4	0.0	38	28	5	5	69	82	62	39	596,982	46,126,375	73,977	11.0	804,354
Stimulants/Anti-obesity/Anorexia	0.6	0.3	0.1	38	28	5	5	69	82	62	39	137,632	9,504,439	22,369	3.3	247,236
Miscellaneous Psychological/Neurological Agents	0.5	0.3	0.0	46	41	0	5	89	145	7	22	5,817	520,289	1,040	0.2	11,433
Analgesics and Anesthetics	0.4	0.0	0.0	10	5	1	4	28	121	47	13	553,483	15,252,381	145,041	21.6	1,558,535
Neuromuscular Agents	0.6	0.3	0.1	39	31	3	6	61	114	54	18	312,603	19,040,151	44,186	6.6	483,821
Nutritional Products	0.3	0.0	0.1	6	1	1	4	19	50	16	18	128,001	2,470,791	37,262	5.5	380,833
Hematological Agents	0.4	0.1	0.0	63	55	1	7	165	441	25	32	71,983	11,857,914	18,168	2.7	189,380
Topical Products	0.2	0.1	0.0	7	4	1	2	32	49	46	16	394,229	12,459,815	169,074	25.2	1,811,508
Miscellaneous Products	0.5	0.2	0.0	64	49	9	6	138	324	272	21	15,389	2,126,393	3,310	0.5	33,405
Unknown Therapeutic Category	0.2	0.0	0.0	3	0	0	0	19	0	0	0	4,709	87,467	2,708	0.4	30,292
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	5,380,588	254,288,386	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. Table ND.6 includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2002. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. For information about these therapeutic categories, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

d. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Alabama, 0.1 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. For information about this classification method, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP^{a, b, c}
 NONDUAL BENEFICIARIES, ALABAMA, 2002

Top 10 Drug Groups	Users				Among Users		
	Total Medicaid Rx \$	No. As % of All Benes	No. of Bene Mos	No. of Rx per Bene Mo	\$ per Rx	Rx \$ per Bene Mo	
ANTIPSYCHOTICS	\$26,995,004	25,895	290,493	0.6	\$166	\$93	
ANTIASTHMATIC	19,700,019	127,640	1,396,887	0.3	56	14	
ANTICONVULSANT	16,517,173	29,953	332,167	0.6	82	50	
ANTIDEPRESSANTS	16,082,105	59,002	641,937	0.4	57	25	
ANTI-DIABETIC	9,630,690	23,609	259,783	0.6	61	37	
STIMULANTS/ANTI-OBESITY/ANOREXIANTS	9,504,405	25,845	287,413	0.5	69	33	
ANTIHISTAMINES	9,092,464	135,189	1,483,744	0.2	36	6	
MISC. HEMATOLOGICAL	8,928,564	3,461	37,596	0.5	460	237	
ANALGESICS - Narcotic	8,747,633	137,361	1,480,093	0.2	26	6	
PASSIVE IMMUNIZING AGENTS	8,641,090	2,098	19,820	0.4	1,200	436	
Total	133,839,147	570,053	6,229,933	n.a.	n.a.	n.a.	

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. Table ND.7 includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2002. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7A
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR TOP 10 DRUG GROUPS COMBINED
 AND FIRST AND SECOND GROUPS SEPARATELY, BY SEX, BOE, AND AGE^{a,b,c}
 NONDUAL BENEFICIARIES, ALABAMA, 2002

Beneficiary Characteristics	All Top 10 Drug Groups					ANTI-PSYCHOTICS					ANTI-ASTHMATIC						
	No. of Rx	Rx \$	No. of Users	Users as % of All Benes	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$	No. of Users	Users as % of All Benes	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$	No. of Users	Users as % of All Benes	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$
All	1,910,307	\$133,839,147	25,895	3.9 %	290,493	0.6	\$93	127,640	19.0 %	1,396,887	0.3	\$14					
Female	1,140,720	70,304,194	14,460	3.5	161,975	0.5	88	64,429	15.6	707,196	0.3	14					
Disabled	749,942	51,263,379	11,962	20.8	136,180	0.6	97	22,543	39.3	257,076	0.4	19					
5 and younger	12,280	2,177,787	36	1.2	419	0.4	46	1,683	57.4	19,152	0.3	21					
6-14	39,858	3,159,109	582	9.4	6,812	0.5	70	2,079	33.5	24,460	0.3	20					
15-20	25,596	2,039,401	587	12.9	6,758	0.5	77	925	20.3	10,744	0.3	17					
21-44	230,156	16,159,374	4,962	25.7	56,033	0.5	91	5,879	30.5	67,139	0.3	15					
45-64	423,798	26,622,381	5,549	24.0	63,302	0.6	106	11,541	49.9	130,523	0.4	21					
65-74	15,970	984,966	207	18.7	2,418	0.7	128	395	35.6	4,582	0.5	24					
75-84	2,047	109,659	33	17.2	366	0.6	84	38	19.8	440	0.7	22					
85 and older	237	10,702	6	14.3	72	0.5	40	3	7.1	36	0.2	5					
Other Eligibles	390,778	19,040,815	2,498	0.7	25,795	0.3	39	41,886	11.8	450,120	0.2	11					
5 and younger	83,576	5,279,360	64	0.1	719	0.4	43	19,434	23.2	209,482	0.2	10					
6-14	118,236	6,522,371	570	0.7	6,378	0.4	42	13,072	15.6	143,901	0.2	13					
15-20	61,729	2,501,311	523	1.0	5,548	0.3	37	4,334	8.5	45,964	0.2	11					
21-44	111,054	3,951,328	1,143	0.9	11,176	0.3	36	4,576	3.4	46,071	0.2	9					
45-64	10,695	485,493	100	4.2	953	0.3	31	330	13.9	3,245	0.3	14					
65-74	1,205	64,231	19	10.4	202	0.6	89	23	12.6	246	0.3	11					
75-84	2,657	148,608	36	13.5	376	0.6	78	78	29.3	852	0.5	31					
85 and older	1,626	88,113	43	15.2	443	0.7	59	39	13.8	359	0.3	10					
Male	767,595	63,281,036	11,433	4.5	128,497	0.6	100	62,489	24.8	683,891	0.2	14					
Disabled	427,535	42,116,967	9,325	18.1	105,686	0.6	110	15,252	29.6	172,144	0.4	20					
5 and younger	19,592	3,321,124	126	3.3	1,489	0.4	54	2,776	71.8	31,941	0.3	22					
6-14	91,609	9,971,343	1,811	15.5	21,134	0.5	74	4,328	37.1	50,550	0.3	19					
15-20	40,553	5,574,057	1,203	15.7	13,785	0.5	90	1,368	17.9	15,919	0.3	16					
21-44	116,748	12,468,682	3,752	26.1	41,894	0.7	128	1,861	12.9	20,671	0.3	17					
45-64	154,056	10,504,523	2,349	17.5	26,411	0.7	124	4,775	35.5	51,389	0.5	23					
65-74	4,303	244,431	65	15.7	759	0.8	106	127	30.7	1,473	0.5	20					
75-84	552	25,618	15	23.4	169	0.6	33	13	20.3	155	0.4	27					
85 and older	122	7,189	4	21.1	45	0.6	63	4	21.1	46	0.1	2					
Other Eligibles	340,060	21,164,069	2,108	1.1	22,811	0.4	52	47,237	23.5	511,747	0.2	12					
5 and younger	110,531	7,478,225	166	0.2	1,881	0.3	38	26,688	30.6	286,874	0.2	11					
6-14	178,898	10,820,628	1,220	1.4	13,616	0.4	51	17,306	20.6	190,198	0.2	14					
15-20	39,038	2,265,329	596	2.2	6,218	0.4	56	2,924	10.8	31,582	0.2	13					
21-44	7,116	349,153	74	4.8	581	0.4	57	169	10.9	1,528	0.2	13					
45-64	2,030	102,730	11	3.3	86	0.3	49	82	24.6	823	0.3	15					
65-74	603	29,247	8	8.4	87	0.6	47	26	27.4	288	0.5	25					
75-84	1,123	72,498	18	14.5	194	0.8	116	27	21.8	293	0.4	25					
85 and older	721	46,259	15	14.9	148	0.8	100	15	14.9	161	0.4	29					
Unknown	1,992	253,917	2	0.0	21	0.7	99	722	12.5	5,800	0.2	8					

Table ND7A

Nondual Beneficiaries

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. Table ND.7A includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2002. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7B
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY,
 BY SEX, BOE, AND AGE^{a, b, c}
 NONDUAL BENEFICIARIES, ALABAMA, 2002

Beneficiary Characteristics	ANTICONVULSANT					ANTIDEPRESSANTS					ANTIDIABETIC				
	No. of Users	Users as % of All Benes	No. of Bene Mos among Users	Mean Rx \$	Mean No. of Rx	No. of Users	Users as % of All Benes	No. of Bene Mos among Users	Mean Rx \$	Mean No. of Rx	No. of Users	Users as % of All Benes	No. of Bene Mos among Users	Mean Rx \$	Mean No. of Rx
All	29,953	4.5 %	332,167	\$50	0.6	59,002	8.8 %	641,937	\$25	0.4	23,609	3.5 %	269,783	\$37	0.6
Female	18,166	4.4	201,741	48	0.6	41,397	10.0	449,942	25	0.4	17,885	4.3	198,632	37	0.6
Disabled	14,547	25.3	164,802	52	0.6	27,081	47.2	304,973	28	0.5	15,103	26.3	170,613	38	0.6
5 and younger	353	12.0	3,999	91	0.7	28	1.0	334	8	0.2	5	0.2	60	41	0.8
6-14	1,080	17.4	12,567	77	0.7	887	14.3	10,378	25	0.5	71	1.1	837	51	0.7
15-20	755	16.6	8,740	76	0.7	1,040	22.9	12,008	26	0.4	154	3.4	1,753	39	0.6
21-44	5,738	29.7	64,557	52	0.6	10,352	53.7	116,022	26	0.4	3,115	16.1	35,418	34	0.5
45-64	6,412	27.7	72,533	43	0.6	14,379	62.2	161,644	30	0.5	11,120	48.1	125,146	39	0.6
65-74	173	15.6	2,007	32	0.6	339	30.6	3,921	27	0.6	568	51.2	6,578	40	0.7
75-84	29	15.1	336	29	0.6	47	24.5	559	25	0.5	63	32.8	745	33	0.6
85 and older	7	16.7	63	14	0.5	9	21.4	107	16	0.6	7	16.7	76	20	0.4
Other Eligibles	3,619	1.0	36,939	29	0.4	14,316	4.0	144,969	18	0.3	2,782	0.8	28,019	28	0.5
5 and younger	287	0.3	3,094	39	0.4	140	0.2	1,597	9	0.3	21	0.0	228	37	0.6
6-14	689	0.8	7,639	37	0.5	2,334	2.8	25,879	17	0.3	277	0.3	2,991	47	0.7
15-20	586	1.1	6,144	34	0.4	3,404	6.7	35,458	18	0.3	332	0.6	3,279	33	0.5
21-44	1,801	1.3	17,555	24	0.3	7,583	5.6	73,736	17	0.3	1,586	1.2	15,967	22	0.4
45-64	194	8.2	1,854	26	0.4	661	27.8	6,341	22	0.4	401	16.9	3,899	33	0.5
65-74	20	11.0	208	24	0.7	41	22.5	413	29	0.6	61	33.5	624	29	0.6
75-84	24	9.0	258	32	0.6	71	26.7	746	37	0.7	79	29.7	815	30	0.8
85 and older	18	6.4	187	32	0.6	82	29.1	799	30	0.6	25	8.9	216	27	0.7
Male	11,780	4.7	130,386	53	0.6	17,599	7.0	191,944	25	0.4	5,724	2.3	61,151	39	0.6
Disabled	9,600	18.6	107,277	57	0.7	11,564	22.5	127,701	27	0.5	5,087	9.9	54,915	39	0.6
5 and younger	432	11.2	4,912	62	0.7	74	1.9	868	16	0.3	11	0.3	126	31	0.4
6-14	1,737	14.9	20,168	66	0.7	2,189	18.8	25,471	26	0.5	79	0.7	911	45	0.7
15-20	1,147	15.0	12,986	71	0.7	1,360	17.8	15,567	28	0.4	113	1.5	1,290	40	0.6
21-44	3,535	24.6	39,101	61	0.7	3,732	26.0	40,220	29	0.5	1,177	8.2	12,968	38	0.6
45-64	2,656	19.8	29,087	40	0.6	4,114	30.6	44,505	27	0.5	3,576	26.6	38,132	39	0.6
65-74	84	20.3	925	41	0.8	76	18.4	864	30	0.6	109	26.3	1,252	31	0.6
75-84	8	12.5	88	47	0.6	12	18.8	131	16	0.6	21	32.8	226	21	0.7
85 and older	1	5.3	10	99	2.1	7	36.8	75	18	0.4	1	5.3	10	6	0.2
Other Eligibles	2,180	1.1	23,109	34	0.4	6,035	3.0	64,243	21	0.4	637	0.3	6,236	40	0.7
5 and younger	427	0.5	4,727	31	0.4	171	0.2	1,888	12	0.3	55	0.1	615	26	0.5
6-14	967	1.1	10,599	33	0.4	3,558	4.2	39,218	20	0.4	184	0.2	1,951	42	0.7
15-20	503	1.9	5,344	40	0.4	1,694	6.3	17,738	24	0.4	152	0.6	1,515	56	0.7
21-44	205	13.3	1,691	35	0.5	426	27.6	3,612	22	0.4	111	7.2	874	34	0.5
45-64	43	12.9	382	22	0.3	115	34.5	1,046	21	0.4	66	19.8	539	30	0.5
65-74	6	6.3	61	12	0.6	19	20.0	193	23	0.5	19	20.0	198	34	0.7
75-84	20	16.1	225	48	0.6	31	25.0	323	35	0.7	34	27.4	389	30	0.7
85 and older	9	8.9	80	46	0.7	21	20.8	225	38	0.7	16	15.8	155	21	0.7
Unknown	7	0.1	40	33	0.4	6	0.1	51	35	0.4	0	0.0	0	0	0.0

Table ND7B
 Nondual Beneficiaries

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

- a. Table ND.7B includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2002. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7C
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY,
 BY SEX, BOE, AND AGE^{a, b, c}
 NONDUAL BENEFICIARIES, ALABAMA, 2002

Beneficiary Characteristics	STIMULANTS/ANTI-OBESITY/ANOREXIANTS					ANTIHISTAMINES					MISC. HEMATOLOGICAL				
	No. of Users	Users as % of All Benes	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$	No. of Users	Users as % of All Benes	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$	No. of Users	Users as % of All Benes	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$
All	25,845	3.8 %	287,413	0.5	\$33	135,189	20.1 %	1,483,744	0.2	\$6	3,461	0.5 %	37,596	0.5	\$238
Female	7,168	1.7	80,046	0.5	31	74,447	18.0	814,670	0.2	6	2,216	0.5	24,435	0.5	51
Disabled	2,341	4.1	27,049	0.5	35	14,216	24.8	164,144	0.2	6	2,054	3.6	22,898	0.5	49
5 and younger	58	2.0	678	0.3	16	986	33.7	11,400	0.2	5	0	0.0	0	0.0	0
6-14	1,348	21.7	15,759	0.5	37	2,015	32.5	23,753	0.2	10	5	0.1	50	0.6	1,708
15-20	292	6.4	3,377	0.4	30	1,072	23.6	12,460	0.2	8	11	0.2	116	0.4	105
21-44	344	1.8	3,849	0.4	34	4,468	23.2	51,319	0.2	4	251	1.3	2,784	0.4	40
45-64	296	1.3	3,350	0.4	34	5,472	23.7	62,799	0.3	4	1,652	7.1	18,400	0.5	46
65-74	1	0.1	12	0.1	6	181	16.3	2,149	0.3	5	110	9.9	1,257	0.6	53
75-84	2	1.0	24	0.6	111	20	10.4	240	0.3	4	22	11.5	263	0.5	42
85 and older	0	0.0	0	0.0	0	2	4.8	24	0.1	1	3	7.1	28	0.5	48
Other Eligibles	4,827	1.4	52,997	0.4	30	60,231	16.9	650,526	0.2	6	162	0.0	1,537	0.4	69
5 and younger	356	0.4	4,023	0.3	17	23,490	28.0	256,446	0.1	4	0	0.0	0	0.0	0
6-14	3,880	4.6	42,604	0.5	31	21,648	25.8	238,941	0.2	9	2	0.0	17	0.1	3
15-20	422	0.8	4,626	0.4	30	8,099	15.8	84,739	0.2	6	1	0.0	12	0.1	2
21-44	154	0.1	1,592	0.3	28	6,676	5.0	67,283	0.2	3	58	0.0	538	0.3	116
45-64	13	0.5	128	0.2	16	235	9.9	2,253	0.2	4	44	1.9	370	0.4	41
65-74	0	0.0	0	0.0	0	21	11.5	199	0.2	5	8	4.4	88	0.6	53
75-84	2	0.8	24	0.1	2	35	13.2	396	0.3	8	28	10.5	292	0.6	46
85 and older	0	0.0	0	0.0	0	27	9.6	269	0.2	2	21	7.4	220	0.7	49
Male	18,676	7.4	207,355	0.5	34	60,287	23.9	665,268	0.2	7	1,245	0.5	13,161	0.6	585
Disabled	5,979	11.6	69,551	0.5	36	9,252	18.0	106,668	0.2	8	1,179	2.3	12,556	0.6	603
5 and younger	245	6.3	2,841	0.3	17	1,520	39.3	17,736	0.2	5	9	0.2	107	1.1	4,520
6-14	4,489	38.5	52,341	0.5	37	3,712	31.8	43,722	0.2	11	19	0.2	228	2.0	12,933
15-20	1,046	13.7	12,205	0.5	38	1,114	14.6	12,962	0.2	10	13	0.2	149	1.7	13,159
21-44	127	0.9	1,402	0.5	38	1,381	9.6	15,549	0.2	4	121	0.8	1,267	0.6	1,329
45-64	71	0.5	750	0.5	40	1,473	11.0	16,136	0.3	4	985	7.3	10,461	0.5	46
65-74	1	0.2	12	0.6	8	44	10.6	471	0.2	4	27	6.5	284	0.5	38
75-84	0	0.0	0	0.0	0	8	12.5	92	0.3	9	5	7.8	60	0.5	45
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Other Eligibles	12,697	6.3	137,804	0.5	32	51,035	25.4	558,600	0.2	7	66	0.0	605	0.5	198
5 and younger	950	1.1	10,592	0.3	18	25,705	29.5	279,831	0.1	4	4	0.0	42	0.2	682
6-14	10,622	12.6	115,236	0.5	33	21,666	25.7	239,268	0.2	9	3	0.0	29	0.6	2,256
15-20	1,108	4.1	11,843	0.5	35	3,489	12.9	37,915	0.2	8	1	0.0	11	0.5	50
21-44	13	0.8	92	0.5	29	118	7.6	1,037	0.2	4	13	0.8	105	0.6	52
45-64	3	0.9	32	0.4	37	27	8.1	212	0.3	8	18	5.4	128	0.3	24
65-74	1	1.1	9	0.6	14	5	5.3	58	0.2	3	7	7.4	80	0.5	46
75-84	0	0.0	0	0.0	0	14	11.3	157	0.1	2	11	8.9	112	0.7	57
85 and older	0	0.0	0	0.0	0	11	10.9	122	0.2	3	9	8.9	98	0.9	69
Unknown	1	0.0	12	0.1	2	455	7.9	3,806	0.2	3	0	0.0	0	0.0	0

Table ND7C

Nondual Beneficiaries

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

- a. Table ND.7C includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2002. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7D
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR NINTH AND TENTH TOP DRUG GROUPS
 SEPARATELY, BY SEX, BOE, AND AGE^{a, b, c}
 NONDUAL BENEFICIARIES, ALABAMA, 2002

Beneficiary Characteristics	ANALGESICS - Narcotic				PASSIVE IMMUNIZING AGENTS							
	No. of Users	Users as % of All Benes	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$	No. of Users	Users as % of All Benes	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$	No. of Benes	No. of Bene Mos
All	137,361	20.4 %	1,480,093	0.2	\$6	2,098	0.3 %	19,820	0.4	\$436	671,804	6,590,109
Female	98,910	23.9	1,062,379	0.2	6	972	0.2	9,395	0.3	412	413,838	4,088,422
Disabled	42,283	73.6	480,881	0.3	10	355	0.6	3,607	0.4	518	57,431	624,580
5 and younger	288	9.8	3,348	0.1	1	340	11.6	3,435	0.4	382	2,930	30,888
6-14	878	14.1	10,302	0.1	2	0	0.0	0	0.0	0	6,205	70,810
15-20	1,637	36.0	18,895	0.2	2	3	0.1	35	0.2	463	4,551	50,912
21-44	16,856	87.4	191,527	0.3	9	9	0.0	101	0.7	3,508	19,295	210,536
45-64	21,849	94.6	247,763	0.4	12	3	0.0	36	1.0	5,183	23,107	246,131
65-74	669	60.3	7,814	0.3	8	0	0.0	0	0.0	0	1,109	12,738
75-84	91	47.4	1,067	0.4	6	0	0.0	0	0.0	0	192	2,128
85 and older	15	35.7	165	0.3	13	0	0.0	0	0.0	0	42	437
Other Eligibles	56,627	15.9	581,498	0.2	2	617	0.2	5,788	0.3	346	356,407	3,463,842
5 and younger	3,812	4.5	42,302	0.1	1	571	0.7	5,315	0.3	362	83,861	790,877
6-14	7,572	9.0	83,416	0.1	1	2	0.0	24	0.3	1,435	83,914	836,040
15-20	14,885	29.1	152,544	0.1	1	15	0.0	150	0.1	20	51,161	463,163
21-44	28,961	21.6	289,756	0.2	3	29	0.0	299	0.1	151	134,363	1,349,609
45-64	1,147	48.2	10,931	0.3	7	0	0.0	0	0.0	0	2,378	18,025
65-74	59	32.4	618	0.2	5	0	0.0	0	0.0	0	182	1,756
75-84	110	41.4	1,135	0.3	14	0	0.0	0	0.0	0	266	2,374
85 and older	81	28.7	796	0.4	13	0	0.0	0	0.0	0	282	1,998
Male	38,406	15.2	417,301	0.2	7	1,046	0.4	9,972	0.4	459	252,171	2,468,970
Disabled	19,096	37.1	210,130	0.3	12	368	0.7	3,865	0.4	507	51,489	544,225
5 and younger	409	10.6	4,749	0.1	1	357	9.2	3,736	0.4	426	3,865	41,569
6-14	1,522	13.0	17,900	0.1	2	3	0.0	36	1.1	1,538	11,667	132,973
15-20	1,792	23.4	20,693	0.1	2	3	0.0	36	0.9	2,300	7,645	84,195
21-44	6,624	46.1	72,644	0.3	11	4	0.0	46	1.2	3,825	14,380	149,280
45-64	8,549	63.6	91,903	0.4	17	1	0.0	11	1.2	4,928	13,435	130,742
65-74	175	42.3	1,973	0.4	10	0	0.0	0	0.0	0	414	4,567
75-84	19	29.7	206	0.3	8	0	0.0	0	0.0	0	64	692
85 and older	6	31.6	62	0.5	30	0	0.0	0	0.0	0	19	207
Other Eligibles	19,310	9.6	207,171	0.1	2	678	0.3	6,107	0.4	428	200,682	1,924,745
5 and younger	4,848	5.6	53,576	0.1	1	677	0.8	6,095	0.4	429	87,265	819,919
6-14	7,739	9.2	85,330	0.1	1	1	0.0	12	0.1	252	84,153	836,337
15-20	5,346	19.8	56,677	0.1	1	0	0.0	0	0.0	0	27,065	253,206
21-44	1,050	67.9	8,596	0.4	14	0	0.0	0	0.0	0	1,546	10,115
45-64	225	67.6	1,919	0.4	18	0	0.0	0	0.0	0	333	2,253
65-74	27	28.4	274	0.3	7	0	0.0	0	0.0	0	95	849
75-84	39	31.5	423	0.3	5	0	0.0	0	0.0	0	124	1,211
85 and older	36	35.6	376	0.3	12	0	0.0	0	0.0	0	101	855
Unknown	45	0.8	413	0.1	1	80	1.4	453	0.4	425	5,795	32,717

Table ND7D

Nondual Beneficiaries

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

- a. Table ND.7D includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2002. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

TABLE ND.8
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,
 BY BENEFICIARY CHARACTERISTIC^{a, b}
 NONDUAL BENEFICIARIES, ALABAMA, 2002

Beneficiary Characteristics	Rx \$ per Bene Mo	No. of Rx per Bene Mo	No. of All-Year NF Residents	Bene Mos among All-Year NF Residents
All	\$328	6.5	1,033	10,668
Age				
0-64	346	6.6	748	7,909
65-74	341	6.8	77	775
75-84	294	6.7	102	1,005
85 and older	210	5.3	106	979
Unknown	0	0.0	0	0
Gender				
Female	339	6.8	591	6,140
Male	314	6.2	440	4,518
Unknown	267	4.0	2	10
Race				
White	339	7	570	5,746
African American	314	6	375	3,960
Other/unknown	320	6.3	88	962
Basis of Eligibility^c				
Aged	250	6.0	203	1,887
Disabled	345	6.6	829	8,770
Adults	0	0.0	0	0
Children	53	3.2	1	11
Unknown	0	0.0	0	0

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. Table ND.8 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their 2002 Medicaid enrollment. A total of 646 beneficiaries who were in nursing facilities for part of their enrollment and their 6,506 benefit months were excluded from the analysis. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

TABLE ND.9
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,
 BY BRAND STATUS AND THERAPEUTIC CATEGORY^{a, b, c, d, e}
 NONDUAL BENEFICIARIES, ALABAMA, 2002

Therapeutic Category	No. of Rx per Bene Mo among Users			\$ per Bene Mo among Users			\$ per Rx			Users								
	Total	Patented Brand-Name	Off-Patent Brand-Name	Total	Patented Brand-Name	Off-Patent Brand-Name	Total	Patented Brand-Name	Off-Patent Brand-Name	Total # of Rx	Total Rx \$	No.	As % of All-Year NF Residents	No. of Bene Mos				
Anti-infective Agents	0.4	0.2	0.0	0.1	\$29	\$24	\$2	\$3	\$3	\$77	\$115	\$94	\$21	2,979	\$228,298	744	72.0 %	7,900
Biologicals	0.1	0.1	0.0	0.0	1	1	0	0	0	12	11	0	17	145	1,763	131	12.7	1,485
Antineoplastic Agents	0.4	0.1	0.1	0.3	94	32	28	34	34	225	619	276	128	446	100,188	106	10.3	1,070
Endocrine/Metabolic Drugs	1.1	0.6	0.1	0.4	45	37	3	6	6	42	64	30	15	5,006	210,533	442	42.8	4,628
Cardiovascular Agents	2.0	0.6	0.2	1.2	59	34	6	19	19	30	60	32	16	12,307	372,289	613	59.3	6,278
Respiratory Agents	0.7	0.2	0.1	0.4	25	15	2	8	8	36	61	35	20	3,773	134,353	504	48.8	5,400
Gastrointestinal Agents	1.1	0.3	0.0	0.8	43	25	0	18	18	40	99	39	21	6,510	258,636	564	54.6	6,047
Genitourinary Agents	0.6	0.4	0.0	0.2	29	26	0	3	3	51	65	28	19	1,188	60,993	191	18.5	2,073
CNS Drugs	1.6	0.8	0.1	0.7	115	97	4	13	13	72	117	71	19	12,603	911,949	761	73.7	7,931
Stimulants/Anti-obesity/Anorexia	0.8	0.6	0.1	0.2	100	89	3	7	7	119	154	58	36	97	11,558	11	1.1	116
Miscellaneous Psychological/Neurological Agents	0.7	0.7	0.0	0.0	88	88	0	1	1	121	124	0	22	759	91,877	100	9.7	1,039
Analgesics and Anesthetics	0.8	0.2	0.1	0.6	42	29	4	9	9	51	136	63	17	4,475	226,931	516	50.0	5,381
Neuromuscular Agents	1.5	0.5	0.3	0.8	87	54	13	21	21	57	107	50	27	9,476	541,728	577	55.9	6,192
Nutritional Products	0.8	0.0	0.1	0.7	11	0	2	9	9	14	17	17	13	3,864	53,185	454	43.9	4,728
Hematological Agents	0.9	0.4	0.2	0.3	56	48	3	4	4	64	137	17	13	2,781	177,199	306	29.6	3,158
Topical Products	0.4	0.2	0.0	0.2	16	10	2	4	4	36	53	50	19	2,882	104,839	603	58.4	6,537
Miscellaneous Products	0.4	0.1	0.0	0.3	18	5	2	11	11	44	90	241	31	257	11,180	59	5.7	628
Unknown Therapeutic Category	0.2	0.0	0.0	0.0	8	0	0	0	0	34	0	0	0	93	3,178	33	3.2	390
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	69,641	3,500,677	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

- a. Table ND.9 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2002. A total of 646 beneficiaries who were in nursing facilities for part of their enrollment and their 6,506 benefit months were excluded from the analysis.
- b. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2002. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- d. For information about these therapeutic categories, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).
- e. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. For information about this classification method, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003). In Alabama, 0.1 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined.

Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS,
 BY TOP-10 DRUG GROUP^{a, b, c, d}
 NONDUAL BENEFICIARIES, ALABAMA, 2002

Top 10 Drug Groups in Nursing Facilities	Users				Among Users		
	Total Medicaid Rx \$	No. of Users	As % of All-Year NF Residents	No. of Bene Mos	No. of Rx per Bene Mo	\$ per Rx	Rx \$ per Bene Mo
ANTIPSYCHOTICS	\$548,698	423	40.9 %	4,596	0.8	\$149	\$119
ANTICONVULSANT	470,488	667	64.6	7,424	1.0	64	63
ANTIDEPRESSANTS	303,911	605	58.6	6,362	0.8	59	48
ULCER DRUGS	178,003	539	52.2	5,852	0.7	45	30
ANTIDIABETIC	170,620	411	39.8	4,383	0.9	45	39
ANALGESICS - Narcotic	163,628	531	51.4	5,537	0.5	57	30
ANTIHYPERTENSIVE	120,739	409	39.6	4,289	0.8	34	28
ANTINEOPLASTICS	100,188	101	9.8	1,037	0.4	225	97
CEPHALOSPORINS	99,734	456	44.1	5,076	0.1	140	20
MISC PSYCHOTHERAPEUTIC AND NEUROLOGICAL	90,992	98	9.5	1,039	0.7	121	88
Total	2,247,001	4,240		45,595	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

- a. Table ND.10 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2002. A total of 646 beneficiaries who were in nursing facilities for part of their enrollment and their 6,506 benefit months were excluded from the analysis.
 - b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
 - c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
 - d. The top 10 drug groups were determined based on total 2002 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).
- Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10A

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR TOP 10 DRUG GROUPS COMBINED AND FIRST AND SECOND TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BOE, AND AGE^{a, b, c, d}
NONDUAL BENEFICIARIES, ALABAMA, 2002

Beneficiary Characteristics	All Top 10 Drug Groups						ANTIPSYCHOTICS						ANTICONVULSANT											
	No. of Rx	Rx \$	Users as %			Mean Rx \$	Mean No. of Rx	No. of Users	No. of Bene Mos among Users	NF Residents	All-Year Residents	Users as %	No. of Users	No. of Bene Mos among Users	NF Residents	All-Year Residents	Users as %	No. of Users	No. of Bene Mos among Users	NF Residents	All-Year Residents	Mean Rx \$	Mean No. of Rx	
			423	40.9 %	4,596																			0.8
All	32,229	\$2,247,001	423	40.9 %	4,596	0.8	\$119	667	64.6 %	7,424	1.0	\$63												
Female	19,031	1,315,648	271	45.9	2,928	0.8	118	344	58.2	3,873	1.0	60												
Disabled	15,457	1,112,212	208	46.7	2,285	0.8	130	316	71.0	3,599	1.0	63												
64 or younger	13,654	996,317	180	45.9	1,964	0.8	134	287	73.2	3,282	1.0	66												
65-74	1,260	81,712	21	60.0	237	0.8	115	20	57.1	217	0.9	40												
75-84	506	32,314	6	35.3	72	0.6	102	9	52.9	100	0.6	27												
85 and older	37	1,869	1	100.0	12	0.1	1	0	0.0	0	0.0	0												
Other Eligibles	3,574	203,436	63	43.2	643	0.7	77	28	19.2	274	0.8	21												
64 or younger	3	148	0	0.0	0	0.0	0	0	0.0	0	0.0	0												
65-74	362	24,959	9	56.3	82	0.8	106	9	56.3	86	0.9	26												
75-84	1,520	83,650	19	38.0	184	0.7	94	10	20.0	102	0.8	17												
85 and older	1,689	94,679	35	44.3	377	0.7	62	9	11.4	86	0.7	22												
Male	13,179	929,352	151	34.3	1,659	0.8	121	323	73.4	3,551	1.0	67												
Disabled	11,852	841,874	130	33.9	1,442	0.8	118	307	79.9	3,380	1.0	68												
64 or younger	10,837	773,824	113	31.8	1,245	0.8	120	281	79.2	3,104	1.0	68												
65-74	782	55,035	12	57.1	139	0.8	116	21	100.0	218	1.1	72												
75-84	132	6,288	3	60.0	36	1.0	75	4	80.0	48	0.6	39												
85 and older	101	6,727	2	66.7	22	0.8	122	1	33.3	10	2.1	99												
Other Eligibles	1,327	87,478	21	37.5	217	1.0	139	16	28.6	171	0.8	43												
64 or younger	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0												
65-74	114	3,988	2	40.0	18	0.6	23	1	20.0	9	1.0	14												
75-84	771	55,284	14	48.3	152	0.9	133	11	37.9	124	0.8	41												
85 and older	442	28,206	5	22.7	47	1.4	203	4	18.2	38	0.8	56												
Unknown	19	2,001	1	50.0	9	1.2	189	0	0.0	0	0.0	0												

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. Table ND.10A includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2002. A total of 646 beneficiaries who were in nursing facilities for part of their enrollment and their 6,506 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2002 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10B
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY
 AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BOE, AND AGE^{a,b,c,d}
 NONDUAL BENEFICIARIES, ALABAMA, 2002

Beneficiary Characteristics	ANTIDEPRESSANTS						ULCER DRUGS						ANTIDIABETIC					
	Users as %			Users as %			Users as %			Users as %			Users as %			Users as %		
	No. of Users	No. of Bene Mos among Users	Mean No. of Rx	No. of Users	No. of Bene Mos among Users	Mean No. of Rx	No. of Users	No. of Bene Mos among Users	Mean No. of Rx	No. of Users	No. of Bene Mos among Users	Mean No. of Rx	No. of Users	No. of Bene Mos among Users	Mean No. of Rx	No. of Users	No. of Bene Mos among Users	Mean No. of Rx
All	605	58.6 %	0.8	6,362	0.8	\$48	539	52.2 %	0.7	\$30	411	39.8 %	0.9	4,383	0.9	\$39		
Female	377	63.8	0.8	3,968	0.8	50	296	50.1	0.7	28	268	45.3	0.9	2,869	0.9	40		
Disabled	281	63.1	0.8	3,032	0.8	52	226	50.8	0.6	30	216	48.5	0.9	2,383	0.9	42		
64 or younger	254	64.8	0.8	2,717	0.8	52	205	52.3	0.6	31	176	44.9	0.9	1,951	0.9	41		
65-74	18	51.4	0.8	207	0.8	48	13	37.1	0.7	30	30	85.7	0.9	312	0.9	49		
75-84	9	52.9	0.8	108	0.8	43	7	41.2	0.7	20	10	58.8	0.7	120	0.7	26		
85 and older	0	0.0	0.0	0	0.0	0	1	100.0	0.9	19	0	0.0	0.0	0	0.0	0		
Other Eligibles	96	65.8	0.8	936	0.8	44	70	47.9	0.7	21	52	35.6	0.9	486	0.9	30		
64 or younger	0	0.0	0.0	0	0.0	0	0	0.0	0.0	0	0	0.0	0.0	0	0.0	0		
65-74	10	62.5	0.8	97	0.8	46	9	56.3	0.5	14	4	25.0	0.9	32	0.9	38		
75-84	40	80.0	0.9	405	0.9	48	20	40.0	0.9	26	29	58.0	1.0	293	1.0	35		
85 and older	46	58.2	0.7	434	0.7	40	41	51.9	0.7	20	19	24.1	0.7	161	0.7	20		
Male	228	51.8	0.8	2,394	0.8	44	243	55.2	0.7	33	143	32.5	0.8	1,514	0.8	38		
Disabled	198	51.6	0.8	2,088	0.8	45	219	57.0	0.7	35	122	31.8	0.8	1,300	0.8	39		
64 or younger	175	49.3	0.8	1,843	0.8	47	208	58.6	0.7	35	105	29.6	0.8	1,103	0.8	43		
65-74	16	76.2	0.7	168	0.7	38	8	38.1	0.7	18	12	57.1	0.5	139	0.5	13		
75-84	3	60.0	0.3	36	0.3	6	3	60.0	0.4	6	4	80.0	0.6	48	0.6	15		
85 and older	4	133.3	0.7	41	0.7	28	0	0.0	0.0	0	1	33.3	0.2	10	0.2	6		
Other Eligibles	30	53.6	0.8	306	0.8	39	24	42.9	0.6	23	21	37.5	0.8	214	0.8	32		
64 or younger	0	0.0	0.0	0	0.0	0	0	0.0	0.0	0	0	0.0	0.0	0	0.0	0		
65-74	6	120.0	0.6	55	0.6	10	2	40.0	0.5	18	0	0.0	0.0	0	0.0	0		
75-84	17	58.6	0.9	167	0.9	50	8	27.6	0.8	22	11	37.9	0.8	122	0.8	45		
85 and older	7	31.8	0.6	84	0.6	38	14	63.6	0.5	24	10	45.5	0.7	92	0.7	14		
Unknown	0	0.0	0.0	0	0.0	0	0	0.0	0.0	0	0	0.0	0.0	0	0.0	0		

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. Table ND.10B includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2002. A total of 646 beneficiaries who were in nursing facilities for part of their enrollment and their 6,506 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2002 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10C
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY
 AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BOE, AND AGE^{a, b, c, d}
 NONDUAL BENEFICIARIES, ALABAMA, 2002

Beneficiary Characteristics	ANALGESICS - Narcotic					ANTHYPERTENSIVE					ANTINEOPLASTICS							
	Users as %					Users as %					Users as %							
	No. of Users	No. of Bene Users	Mean No. of Rx	Mean Rx \$	Mean No. of Rx	No. of Users	No. of Bene Users	Mean No. of Rx	Mean Rx \$	Mean No. of Rx	No. of Users	No. of Bene Users	Mean No. of Rx	Mean Rx \$	No. of Users	No. of Bene Users	Mean No. of Rx	Mean Rx \$
All	531	5,537	0.5	\$30	0.8	409	4,289	0.8	\$28	101	1,037	0.4	\$97					
Female	318	3,346	0.6	30	0.8	219	2,316	0.8	28	57	606	0.4	97					
Disabled	239	2,599	0.6	32	0.9	164	1,784	0.9	29	37	410	0.4	115					
64 or younger	212	2,302	0.6	33	0.9	140	1,514	0.9	30	31	338	0.4	114					
65-74	20	221	0.5	27	0.8	15	162	0.8	25	2	24	0.3	95					
75-84	7	76	0.6	12	1.0	8	96	1.0	24	4	48	0.5	130					
85 and older	0	0	0.0	0	1.0	1	12	1.0	26	0	0	0.0	0					
Other Eligibles	79	747	0.5	23	0.8	55	532	0.8	23	20	196	0.5	59					
64 or younger	0	0	0.0	0	0.0	0	0	0.0	0	0	0	0.0	0					
65-74	6	57	0.3	8	0.7	4	32	0.7	18	1	12	0.3	123					
75-84	34	325	0.5	34	0.9	18	191	0.9	31	4	33	0.8	89					
85 and older	39	365	0.4	16	0.8	33	309	0.8	19	15	151	0.4	47					
Male	213	2,191	0.5	29	0.8	190	1,973	0.8	28	44	431	0.4	97					
Disabled	190	1,994	0.5	32	0.8	158	1,650	0.8	31	37	362	0.4	102					
64 or younger	180	1,853	0.5	32	0.8	146	1,525	0.8	31	33	328	0.4	105					
65-74	8	82	0.5	27	0.8	11	113	0.8	33	3	22	0.4	111					
75-84	1	12	0.1	1	1.0	1	12	1.0	30	0	0	0.0	0					
85 and older	1	7	0.9	7	0.0	0	0	0.0	0	1	12	0.5	25					
Other Eligibles	23	237	0.2	3	0.6	32	323	0.6	15	7	69	0.5	67					
64 or younger	0	0	0.0	0	0.0	0	0	0.0	0	0	0	0.0	0					
65-74	4	31	0.5	5	1.0	5	57	0.5	6	0	0	0.0	0					
75-84	14	146	0.2	3	0.6	17	173	0.6	16	4	42	0.4	50					
85 and older	5	60	0.2	2	0.8	10	93	0.8	20	3	27	0.6	93					
Unknown	0	0	0.0	0	0.0	0	0	0.0	0	0	0	0.0	0					

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. Table ND.10C includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2002. A total of 646 beneficiaries who were in nursing facilities for part of their enrollment and their 6,506 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2002 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10D
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR NINTH AND TENTH TOP DRUG GROUPS
 SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BOE, AND AGE^{a, b, c, d}
 NONDUAL BENEFICIARIES, ALABAMA, 2002

Beneficiary Characteristics	CEPHALOSPORINS					MISC PSYCHOTHERAPEUTIC AND NEUROLOGICAL					Bene Mos among All-Year NF Residents	
	Users as %		No. of Bene		Mean Rx	Users as %		No. of Bene		Mean Rx		
	No. of Users	Residents	NF	Users		NF	Users	No. of Rx	No. of Rx			
All	456	44.1 %	5,076	0.1	\$20	98	9.5 %	1,039	0.7	\$88	1,033	10,668
Female	254	43.0	2,857	0.1	19	60	10.2	617	0.7	88	591	6,140
Disabled	193	43.4	2,199	0.1	21	31	7.0	310	0.7	84	445	4,795
64 or younger	176	44.9	2,013	0.1	22	25	6.4	248	0.6	76	392	4,214
65-74	10	28.6	102	0.2	10	3	8.6	26	1.0	130	35	373
75-84	6	35.3	72	0.1	12	2	11.8	24	0.8	103	17	196
85 and older	1	100.0	12	0.2	2	1	100.0	12	0.9	108	1	12
Other Eligibles	61	41.8	658	0.1	12	29	19.9	307	0.8	93	146	1,345
64 or younger	1	100.0	11	0.3	14	0	0.0	0	0.0	0	1	11
65-74	7	43.8	84	0.1	8	2	12.5	24	0.8	158	16	148
75-84	27	54.0	275	0.2	13	7	14.0	68	0.7	89	50	471
85 and older	26	32.9	288	0.1	11	20	25.3	215	0.8	86	79	715
Male	202	45.9	2,219	0.1	20	38	8.6	422	0.7	87	440	4,518
Disabled	190	49.5	2,080	0.1	21	25	6.5	279	0.7	86	384	3,975
64 or younger	182	51.3	1,989	0.1	21	18	5.1	200	0.7	88	355	3,684
65-74	5	23.8	55	0.1	7	5	23.8	55	0.6	86	21	213
75-84	3	60.0	36	0.1	3	1	20.0	12	0.1	11	5	49
85 and older	0	0.0	0	0.0	0	1	33.3	12	1.8	125	3	29
Other Eligibles	12	21.4	139	0.1	17	13	23.2	143	0.8	89	56	543
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
65-74	2	40.0	19	0.1	95	1	20.0	9	0.9	26	5	41
75-84	3	10.3	36	0.1	9	7	24.1	78	0.8	107	29	288
85 and older	7	31.8	84	0.1	2	5	22.7	56	0.7	75	22	214
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	10

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. Table ND.10D includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2002. A total of 646 beneficiaries who were in nursing facilities for part of their enrollment and their 6,506 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2002 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Table ND10D

Nondual Beneficiaries

TABLE ND.11
 USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D
 AMONG NONDUALS, BY BENEFICIARY CHARACTERISTIC^{a,b}
 ALABAMA, 2002

Beneficiary Characteristics	No. of Benes with at Least One Part D Excl Rx	% Benes with at Least One Part D Excl Rx	No. of Part D Excl Rx per Bene	Total No. Part D Excl Rx	Part D Excl Rx \$ per Bene	Total Part D Excl Rx \$	\$ per Part D Excl Rx	Part D Excl Rx \$ as % of All Nonduals Rx \$	Total No. of Benes
Age									
5 and younger	92,172	50.2	1.4	248,775	24	4,486,248	18	10.9	183,691
6-14	57,961	31.2	0.7	128,554	18	3,297,063	26	6.4	185,952
15-20	21,192	23.4	0.5	48,888	15	1,363,687	28	5.8	90,429
21-44	29,187	17.2	0.7	124,077	16	2,778,083	22	4.8	169,585
45-64	21,779	55.5	4.4	174,534	84	3,309,612	19	4.4	39,253
65-74	957	53.1	4.5	8,162	72	128,995	16	4.3	1,801
75-84	326	50.4	4.6	2,992	54	34,784	12	3.7	647
85 and older	165	37.0	3.7	1,667	39	17,419	10	4.2	446
Unknown	0	0.0	0.0	0	0	0	0	0.0	0
Basis of Eligibility^c									
Aged	435	41.3	3.6	3,830	41	43,066	11	3.6	1,053
Disabled	51,052	46.9	3.0	326,649	78	8,513,458	26	5.2	108,922
Adults	15,359	11.1	0.3	39,776	4	604,115	15	4.7	138,788
Children	156,827	37.1	0.9	367,095	15	6,250,876	17	8.1	422,859
Unknown	66	36.3	1.6	299	24	4,376	15	2.5	182
Gender									
Female	127,260	30.8	1.1	446,785	22	8,969,602	20	6.1	413,838
Male	94,942	37.6	1.1	287,595	25	6,397,669	22	6.0	252,171
Unknown	1,537	26.5	0.6	3,269	8	48,620	15	9.6	5,795
Race									
White	107,396	37.5	1.3	378,221	27	7,858,059	21	5.9	286,010
African American	102,721	29.2	0.9	300,629	18	6,166,343	21	6.2	351,563
Other/unknown	13,622	39.8	1.7	58,799	41	1,391,489	24	6.1	34,231
Use of Nursing Facilities^d									
Entire year	870	84.2	11.9	12,323	164	169,138	14	4.8	1,033
Part year	574	88.9	9.5	6,133	182	117,472	19	5.5	646
None	222,295	33.2	1.1	719,193	23	15,129,281	21	6.1	670,125
Maintenance Assistance Status									
Cash	85,662	40.7	2.0	412,899	46	9,714,808	24	5.3	210,533
Medically needy	0	0.0	0.0	0	0	0	0	0.0	0
Poverty related	129,383	37.8	0.9	302,031	15	5,160,718	17	8.3	342,283
Other/unknown	8,694	7.3	0.2	22,719	5	540,365	24	5.8	118,988

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

- a. Table ND.11 includes the beneficiaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2002.
- b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.
- c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.
- Bene(s) = beneficiary (or beneficiaries); CMS = Center for Medicare and Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.12

USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D
 AMONG NONDUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC^{a,b}
 ALABAMA, 2002

Beneficiary Characteristics	No. Rx per Bene Mo.	Rx \$ per Bene Mo.	\$ per Rx	Barbiturate \$ per Bene Mo.	Benzodiazepine \$ per Bene Mo.	No. of Bene Mos
All	0.1	\$2	\$21	\$0	\$0	6,590,109
Age						
5 and younger	0.1	3	18	0	0	1,715,744
6-14	0.1	2	26	0	0	1,876,284
15-20	0.1	2	28	0	0	851,532
21-44	0.1	2	22	0	0	1,719,552
45-64	0.4	8	19	0	2	397,151
65-74	0.4	6	16	0	1	19,922
75-84	0.5	5	12	0	1	6,406
85 and older	0.5	5	10	0	1	3,518
Unknown	0.0	0	0	0	0	0
Basis of Eligibility^c						
Aged	0.4	5	11	0	1	9,072
Disabled	0.3	7	26	0	2	1,168,829
Adults	0.0	0	15	0	0	1,384,150
Children	0.1	2	17	0	0	4,026,622
Unknown	0.2	3	15	0	1	1,436
Gender						
Female	0.1	2	20	0	0	4,088,422
Male	0.1	3	22	0	0	2,468,970
Unknown	0.1	1	15	0	0	32,717
Race						
White	0.1	3	21	0	0	2,731,544
African American	0.1	2	21	0	0	3,534,187
Other/unknown	0.2	4	24	0	1	324,378
Use of Nursing Facilities^d						
Entire year	1.2	16	14	1	4	10,668
Part year	0.9	18	19	0	4	6,506
None	0.1	2	21	0	0	6,572,935
Maintenance Assistance Status						
Cash	0.2	5	24	0	1	2,142,284
Medically needy	0.0	0	0	0	0	0
Poverty related	0.1	2	17	0	0	3,199,478
Other/unknown	0.0	0	24	0	0	1,248,347

Table ND12

Nondual Beneficiaries

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

- a. Table ND.12 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2002.
 - b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.
 - c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
 - d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.
- Bene(s) = beneficiary (or beneficiaries); CMS = Center for Medicare and Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.13
 USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D
 FOR SELECTED DRUG CATEGORIES AMONG NONDUALS^{a,b,c}
 ALABAMA, 2002

Drug Category	No. Users	Rx \$ per User	Total Rx \$	Rx \$ as % of All Part D Excl Rx \$	Total No. Rx.	\$ per Rx	No. Rx as % of All Part D Excl Rx
All	278,235	\$55	\$15,415,891	100.0 %	737,649	\$21	100.0 %
Anorexia or weight loss/gain	0	0	0	0.0	0	0	0.0
Fertility drugs	9	55	499	0.0	10	50	0.0
Drugs for cosmetic purposes	72	21	1,498	0.0	113	13	0.0
Cough and cold medications	182,859	40	7,317,077	47.5	413,794	18	56.1
Vitamins and minerals	13,933	92	1,282,807	8.3	68,864	19	9.3
Non-prescription drugs	53,408	50	2,670,759	17.3	116,697	23	15.8
Barbiturates	2,209	58	128,781	0.8	17,036	8	2.3
Benzodiazepines	17,087	120	2,045,819	13.3	96,501	21	13.1
Other Part D Excl Rx Drugs	8,658	227	1,968,651	12.8	24,634	80	3.3

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. Table ND.13 includes the beneficiaries represented by Cell K of Table 1. Beneficiaries include all non-dual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2002. A user is a beneficiary who had at least one prescription filled for a Part D excluded drug in 2002. A beneficiary who used drugs from two or more Part D excluded categories was counted as a user for each category. Therefore, the sum of users across drug categories may exceed the total number of individual users as noted on Table ND11.

b. Includes OTC drugs as well as prescription drugs.

c. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.

Bene(s) = beneficiary (or beneficiaries); CMS = Center for Medicare and Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

APPENDIX TABLE A.1

CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY^{a, b}
NONDUAL BENEFICIARIES, ALABAMA, 2002

Beneficiary Characteristics	No. of Beneficiaries					No. of Beneficiaries						
	All	Aged	Disabled	Adults	Children	All	Aged	Disabled	Adults	Children	Unknown	
All	671,827	1,062	108,936	138,788	422,859	182	6,590,419	9,183	1,169,027	1,384,150	4,026,623	1,436
Age												
5 and younger	183,691	0	6,795	0	176,896	0	1,715,745	0	72,457	0	1,643,288	0
6-14	185,952	0	17,872	0	168,080	0	1,876,284	0	203,783	0	1,672,501	0
15-20	90,429	0	12,196	738	77,495	0	851,532	0	135,107	7,773	708,652	0
21-44	169,587	0	33,678	135,477	388	44	1,719,580	0	359,856	1,357,177	2,182	365
45-64	39,261	7	36,550	2,566	0	138	397,242	31	376,964	19,176	0	1,071
65-74	1,805	278	1,527	0	0	0	20,010	2,626	17,384	0	0	0
75-84	653	396	257	0	0	0	6,482	3,650	2,832	0	0	0
85 and older	449	381	61	7	0	0	3,544	2,876	644	24	0	0
Unknown	0	0	0	0	0	0	0	0	0	0	0	0
Gender												
Female	413,847	737	57,435	136,949	218,544	182	4,088,539	6,205	624,636	1,372,184	2,084,078	1,436
Male	252,185	322	51,499	1,839	198,525	0	2,469,163	2,956	544,367	11,966	1,909,874	0
Unknown	5,795	3	2	0	5,790	0	32,717	22	24	0	32,671	0
Race												
White	286,014	529	41,449	63,215	180,720	101	2,731,594	4,131	437,049	618,977	1,670,605	832
African American	351,580	348	54,879	72,781	223,494	78	3,534,419	3,123	605,443	738,699	2,186,567	587
Other/unknown	34,233	185	12,608	2,792	18,645	3	324,406	1,929	126,535	26,474	169,451	17
Use of Nursing Facilities^c												
Entire year	1,034	204	829	0	1	0	10,690	1,899	8,780	0	11	0
Part year	646	84	559	1	2	0	6,510	788	5,697	10	15	0
None	670,147	774	107,548	138,787	422,856	182	6,573,219	6,496	1,154,550	1,384,140	4,026,597	1,436
Maintenance Assistance Status												
Cash	210,554	579	107,331	25,934	76,710	0	2,142,566	6,150	1,156,752	220,762	758,902	0
Medically needy	0	0	0	0	0	0	0	0	0	0	0	0
Poverty related	342,283	14	60	15,752	326,275	182	3,199,478	71	236	119,810	3,077,925	1,436
Other/unknown	118,990	469	1,545	97,102	19,874	0	1,248,375	2,962	12,039	1,043,578	189,796	0
Managed Care Status												
FFS all year	671,794	1,050	108,915	138,788	422,859	182	6,590,055	9,056	1,168,790	1,384,150	4,026,623	1,436
FFS part year, with Rx claims	10	3	7	0	0	0	107	29	78	0	0	0
FFS part year, no Rx claims	0	0	0	0	0	0	0	0	0	0	0	0
MC all year, with Rx claims	16	6	10	0	0	0	192	72	120	0	0	0
MC all year, no Rx claims	7	3	4	0	0	0	65	26	39	0	0	0

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. Table A.1 includes the beneficiaries represented by Cell J of Table 1. Benefit months are months during which beneficiaries had pharmacy benefit coverage.

b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.

c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene Mo(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.

APPENDIX TABLE A.2
 MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS^a
 NONDUAL BENEFICIARIES, ALABAMA, 2002

	Bene Mos in Cell J of Table 1		Bene Mos and		Included in Cell K of Table 1		Excluded from Cell K of Table 1	
	No. of Benes	No. of Bene Mos	No. of Benes	No. of Bene Mos	No. of Benes	No. of Bene Mos	No. of Benes	No. of Bene Mos
All	671,827	6,590,419	671,804	6,590,109	0	310		
FFS all year	671,794	6,590,055	671,794	6,590,054	0	1		
FFS part year, with Rx claims	10	107	10	55	0	52		
FFS part year, with no Rx claims	0	0	0	0	0	0		
MC all year, with Rx claims	16	192	0	0	0	192		
MC all year, with no Rx claims	7	65	0	0	0	65		

Source: Data for this table are from the MAX 2002 file for Alabama, released by CMS in 05/2006. This table was produced on 04/19/2007.

a. Benefit months are months during which beneficiaries had pharmacy benefit coverage.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.